ArticleAmerican journal of translational research2025
Clinical superiority of artificial intelligence-enabled jaundice monitoring follow-up combined with end-tidal carbon monoxide measurement in neonatal jaundice management.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical superiority of artificial intelligence (AI)-enabled jaundice monitoring follow-up combined with end-tidal carbon monoxide (ETCO) measurement in the management of neonatal jaundice.
methodsSixty jaundiced neonates were studied, with 25 assigned to conventional monitoring and follow-up (control group) and 35 to an AI-enabled jaundice monitoring follow-up plus ETCO assessment (research group). Evaluated endpoints comprised bilirubin concentrations (both serum and transcutaneous), prevalence of hyperbilirubinemia (HB), bilirubin encephalopathy (BE), and ABO hemolytic disease, monitoring/procedure-related adverse events, and time to symptom improvement. The assessment also covered alterations (pre- vs. post-intervention) in the Neonatal Behavioral Neurological Assessment (NBNA), Mental Development Index (MDI), and Psychomotor Development Index (PDI) scores, as well as maternal psychological well-being (Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS)) and parental satisfaction.
resultsPost-intervention, the research group exhibited greater reductions in bilirubin, transcutaneous bilirubin, SAS/SDS scores, HB/BE incidence, and overall complications than the control group, coupled with accelerated symptom relief (all P<0.05). Post-intervention assessments also confirmed markedly higher NBNA, MDI, and PDI scores, as well as enhanced parental satisfaction in the research group (all P<0.05).
conclusionAI-enabled jaundice monitoring follow-up combined with ETCO measurement offers significant clinical advantages in neonatal jaundice management, supporting its broader clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.